Law Firm Launches Shareholder Rights Investigations into Four M&A Deals Involving PULM, SLP, OLN, and HUN

Deep News04:00

Merger and acquisition class action law firm Monteverde & Associates PC has announced it is initiating shareholder rights investigations into four proposed public company transactions, involving Pulmatrix, Inc. (NASDAQ: PULM), Simulations Plus (NASDAQ: SLP), Olin Corporation (NYSE: OLN), and Huntsman Corporation (NYSE: HUN). The law firm was recently ranked among the top 50 nationally in the 2025 ISS Securities Class Action Services report.

Major Industry Consolidation Deals

Two of the four deals under investigation represent major consolidation within their respective industries. Chemical giants Olin Corporation and Huntsman Corporation announced an all-stock merger of equals on June 16th, aiming to create a new North American chemical entity named OlinHuntsman with approximately $12.5 billion in annual revenue. Under the terms, Huntsman shareholders will receive 0.5476 Olin shares for each Huntsman share they own. Olin shareholders are expected to own about 54.5% of the combined company, with Huntsman shareholders owning the remaining 45.5%. The companies have identified over $400 million in potential cost synergies. The transaction is anticipated to close in the first half of 2027, with a shareholder vote scheduled for August 25th.

Cash Acquisition of Software Firm

The other significant transaction involves pharmaceutical software company Simulations Plus being acquired by healthcare-focused investment firm Altaris in an all-cash deal valued at approximately $375 million. Shareholders are set to receive $18.50 per share, representing a 26% premium to the 60-day volume-weighted average price. Upon completion, Simulations Plus will be combined with Altaris's portfolio company, Chemical Computing Group. The deal is expected to finalize in the fourth quarter.

Additional Biotech Merger Under Scrutiny

Furthermore, the law firm is investigating the merger of Pulmatrix, Inc. with Eos SENOLYTIX. The biotechnology company announced this reverse merger in March, with Pulmatrix's existing shareholders expected to retain only about 6% of the new combined company. This transaction is also projected to close in the third quarter.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment